Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Positron Corporation (POSC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.6817-0.0982 (-12.60%)
At close: 03:43PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7800
Open0.8080
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6700 - 0.8080
52 Week Range0.0680 - 1.8620
Volume3,300
Avg. Volume4,416
Market Cap9.733M
Beta (5Y Monthly)-0.35
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Positron Corporation Announces Key Sales & Services Personnel Hire

    Niagara Falls, NY, June 24, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging device systems and clinical services company, is pleased to announce that Christopher Reilly has joined Positron to lead the Company’s PET-CT Services and Systems Sales. Through a career spanning over three decades, Mr. Reilly has acquired vast expertise and industry knowledge in all aspects of SPECT imaging systems, services, pharmaceuticals and pra

  • GlobeNewswire

    Positron Corporation Retains FDA Consulting Firm in Preparation for 510K New Device Application

    Niagara Falls, NY , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging device systems and clinical services company, is pleased to announce today that the Company has retained Medical Device Academy ”MDA”) as its consultant for the Company’s new PET/CT device 510K submission with the Food and Drug Administration (“FDA”). Positron will be applying for new device approval to market and sell its PET/CT device in the Unite

  • GlobeNewswire

    Positron Issues Shareholder Letter to Discuss Recent Key Highlights & 2022 Objectives

    Niagara Falls, NY, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging company specializing in the field of cardiac Positron Emission Tomography (“PET”) imaging systems and clinical services, is pleased to issue today the following shareholder letter below. The letter is also available on the Company’s website at: http://www.positron.com/. Positron Corporation Shareholder Letter Dear Positron Shareholders, In considerat

Advertisement
Advertisement